Point-of-Care Diagnostics (POCD) Market By Products (Infectious Disease Testing, Glucose Monitoring, Hematology Testing, Pregnancy and Fertility Testing, Urinalysis Testing, Cardiometabolic Monitoring, Tumors or Cancer Marker Testing, Coagulation Monitoring, Cholesterol Testing, Drugs of Abuse Testing), Prescription Mode (Prescription-based Point-of-Care Diagnostics, Over-the-Counter-based Point-of-Care Diagnostics), End-users (Hospitals, Clinics/Physician Office Laboratory, Home Care, Ambulatory Care), and Regions (North America, Europe, Asia Pacific, Rest of the World): Global Forecast up to 2025
- August, 2019
- Domain: Healthcare - Diagnostics
- Get Free 10% Customization in this Report
This market research report includes a detailed segmentation of the global point-of-care diagnostics market by products (infectious disease testing, glucose monitoring, hematology testing, pregnancy and fertility testing, urinalysis testing, cardiometabolic monitoring, tumors or cancer marker testing, coagulation monitoring, cholesterol testing, drugs of abuse testing, and others), by prescription mode (prescription-based point-of-care diagnostics and over-the-counter-based point-of-care diagnostics), by end-users (hospitals, clinics/physician office laboratory, home care, and ambulatory care), and by regions (North America, Europe, Asia Pacific, and Rest of the World).
Overview of the Global Point-of-Care Diagnostics Market Research:
Infoholic’s market research report predicts that the global point-of-care diagnostics market will grow at a CAGR of 7.3% during the forecast period 2019–2025. The market has witnessed steady growth in the past few years, and the advancements in technology with the launch of innovative products have increased the adoption of point-of-care diagnostics products. The market is fueled by the increasing prevalence of infectious diseases, upsurge in the incidence of lifestyle diseases, increasing geriatric population, and rising adoption of the technology in emerging countries.
The market continues to grow as point-of-care diagnostics is one of the most widely used techniques for screening, diagnosis, and making a treatment decision. Key market players are focusing on product approvals, new launches, and targeting end-user’s perspective. The market generates significant revenue from the key players operating in this field, and few of them include Abbott Laboratories, F. Hoffmann-La Roche, Johnson & Johnson, Danaher Corporation, and Siemens Healthineers Inc. (Siemens AG).
According to Infoholic Research analysis, North America accounted for the largest share of the global point-of-care diagnostics market in 2018, and Asia Pacific is expected to grow at a high CAGR during the forecast period. According to a report released by the Centers for Disease Control and Prevention (CDC), in the US alone, more than 100 million adults are now living with diabetes or prediabetes. According to an estimation, in the US, approximately 1,688,780 new cancer cases were diagnosed and 600,920 cancer deaths were reported in 2017. Canada had an estimated 206,200 new cases of cancer and 80,800 deaths from cancer in 2017. Cardiovascular disease (CVD) accounts for approximately 800,000 deaths in the US, and on an average, one person dies from CVD every 40 seconds in the US. Coronary heart disease accounts for the majority of CVD deaths followed by stroke and heart failure. The presence of dominant players in the region, promising reimbursement facilities, availability of hi-tech medical technologies, and growing patient base for lifestyle diseases make North America the dominant shareholder in the market.
Based on geography, North America dominated the market in 2018 with a share of over 40% and is expected to maintain this position during the forecast period. Asia Pacific is projected to grow at a high CAGR during the forecast period. The increasing incidence of chronic and lifestyle diseases, booming economy, and increasing health awareness among patients make North America the fastest-growing region during the forecast period.
Global Point-of-Care Diagnostics Market Research Competitive Analysis: The market is growing at a steady rate with a CAGR of 7.3% during the forecast period 2019–2025. A lot of new players are concentrating on this market to deliver advanced and innovative products. The increasing adoption of point-of-care diagnostics has resulted in increased approvals, new launches, strategic collaborations, acquisitions, and increased funding. For instance, in February 2019, HemoCue received the FDA approval for its HemoCue Hb 801 System that quantitatively measures hemoglobin in capillary or venous whole blood. In June 2019, Abbott launched its Afinion HbA1c Dx assay available for use on the Afinion 2 Analyzer, as well as the Afinion AS100 Analyzer. Afinion HbA1c Dx assay is the first rapid point-of-care test approved by the FDA to aid healthcare professionals in the diagnosis of diabetes. In March 2019, Group K Diagnostics partnered with the US Centers for Disease Control and Prevention to design and evaluate a prototype reverse transcriptase loop-mediated isothermal amplification assay to detect Zika virus RNA at POC.
- Abbott Laboratories
- Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Danaher Corporation
- Siemens Healthineers Inc. (Siemens AG)
- Trinity Biotech plc
- Qiagen N.V.
- OraSure Technologies Inc.
- Instrumentation Laboratory (IL)
- Becton Dickinson and Company
- Nova Biomedical
Key Competitive Facts:
- The market is highly competitive with all the players competing to gain market shares. Intense competition, rapid advancements in technology, frequent changes in government policies, and the prices are key factors that confront the market.
- The market is moving strongly toward smart devices that are equipped with mobile healthcare (mH). This smart healthcare option is expected to revolutionize personalized healthcare monitoring and management, thus leading the way for next-generation point-of-care testing.
Benefits – The report provides complete details about the sub-segment of the global point-of-care diagnostics market. Thus, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives toward the diagnostics segment in the upcoming years along with details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.
- Understanding the potential market opportunity with precise market size and forecast data
- Detailed market analysis focusing on the growth of point-of-care diagnostics
- Factors influencing the growth of the point-of-care diagnostics
- In-depth competitive analysis of dominant and pure-play vendors.
- Prediction analysis of the point-of-care diagnostics industry in both developed and developing regions.
- Key insights related to major segments of the point-of-care diagnostics
- Latest market trend analysis impacting the buying behavior of the consumers.
1 Industry Outlook
1.1 Industry Overview
1.2 Total Addressable Market
1.3 Industry Trends
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Advantages of Point-of-Care Testing
3.3 Disadvantages of Point-of-Care Testing
3.4 Segmented Addressable Market
3.5 Trends in the Point-of-Care Diagnostics Market
3.6 Related Markets
3.6.1 Molecular Diagnostics
3.6.2 Infectious Disease Diagnostics
4 Market Outlook
4.1 Market Segmentation
4.2 PEST Analysis
4.3 Porter 5 (Five) Forces
5 Market Characteristics
5.1 DRO – Market Dynamics
22.214.171.124 Increasing prevalence of infectious disease
126.96.36.199 Growing incidence of lifestyle disease
188.8.131.52 Technological innovations
184.108.40.206 Increasing adoption of point-of-care diagnostics
220.127.116.11 Growth opportunities in emerging markets
18.104.22.168 Increasing awareness towards point-of-care diagnostics in developing countries
22.214.171.124 Stringent approval process
126.96.36.199 Product recalls
188.8.131.52 Unfavorable reimbursement scenario
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 Product: Market Size and Analysis
6.2 Glucose Monitoring
6.3 Infectious Disease Testing
6.3.1 Influenza Testing
6.3.2 HIV Testing
6.3.3 Hepatitis Testing
6.3.4 Tuberculosis Testing
6.3.5 Sexually Transmitted Diseases Testing
6.3.6 Healthcare-associated Infections Testing
6.3.7 Respiratory Infections Testing
6.4 Pregnancy and Fertility Testing
6.5 Hematology Testing
6.6 Cardiometabolic Monitoring
6.7 Urinalysis Testing
6.8 Coagulation Monitoring
6.9 Tumor or Cancer Marker Testing
6.10 Cholesterol Testing
6.11 Drugs of Abuse Testing
7 Prescription Mode: Market Size and Analysis
7.2 Prescription-based Point-of-Care Diagnostics
7.3 Over the Counter-based Point-of-Care Diagnostics
8 End-users: Market Size and Analysis
8.3 Clinics/Physician Office Laboratory (POL)
8.4 Home Care
8.5 Ambulatory Care
9 Regions: Market Size and Analysis
9.2 North America
9.5 Rest of the World
10 Competitive Landscape
11 Vendors Profile
11.1 Abbott Laboratories
11.1.2 Business Units
11.1.3 Geographic Revenue
11.1.4 Business Focus
11.1.5 SWOT Analysis
11.1.6 Business Strategies
11.2 F. Hoffmann-La Roche Ltd.
11.2.2 Business Units
11.2.3 Geographic Revenue
11.2.4 Business Focus
11.2.5 SWOT Analysis
11.2.6 Business Strategies
11.3 Johnson & Johnson
11.3.2 Business Units
11.3.3 Geographic Revenue
11.3.4 Business Focus
11.3.5 SWOT Analysis
11.3.6 Business Strategies
11.4 Danaher Corporation
11.4.2 Business Units
11.4.3 Geographic Revenue
11.4.4 Business Focus
11.4.5 SWOT Analysis
11.4.6 Business Strategies
11.5 Siemens Healthineers Inc. (Siemens AG)
11.5.2 Business Units
11.5.3 Geographic Revenue
11.5.4 Business Focus
11.5.5 SWOT Analysis
11.5.6 Business Strategies
12 Companies to Watch For
12.1 Trinity Biotech plc
12.2 Qiagen N.V.
12.3 BioMerieux S.A.
12.4 OraSure Technologies Inc.
12.5 Instrumentation Laboratory (A Werfen Company)
12.6 Becton Dickinson and Company
12.7 Nova Biomedical
Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:
- Data Collation (Primary & Secondary)
- In-house Estimation (Based on proprietary data bases and Models)
- Market Triangulation
Market related information is congregated from both primary and secondary sources.
Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.